Preclinical News and Research

RSS
Genmab reports revenues of DKK 107M for first-quarter 2010

Genmab reports revenues of DKK 107M for first-quarter 2010

Exelixis first-quarter revenues increase to $42.2 million

Exelixis first-quarter revenues increase to $42.2 million

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

Enzon reports income from continuing operations of $20.8M for first-quarter 2010

Enzon reports income from continuing operations of $20.8M for first-quarter 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Bovie Medical first-quarter revenues decrease to $5.6M

Bovie Medical first-quarter revenues decrease to $5.6M

Immunomedics third-quarter revenues increase to $10.7 million

Immunomedics third-quarter revenues increase to $10.7 million

Achillion reports lower net loss of $5.6M for first-quarter 2010

Achillion reports lower net loss of $5.6M for first-quarter 2010

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

Cytori Therapeutics to initiate European medical device approval study for Celution System

Cytori Therapeutics to initiate European medical device approval study for Celution System

MicroStockProfit.com releases NexMed investment report

MicroStockProfit.com releases NexMed investment report

Two-day symposium on molecular neuroimaging

Two-day symposium on molecular neuroimaging

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.